High level of mitogen-activated protein kinase phosphatase-1 expression is associated with cisplatin resistance in osteosarcoma

Pediatric Blood and Cancer

Volumn 51, Issue 6, 2008, Pages 754-759

  Wang, Zhihong ^a,c   Zhou, Jun Ying ^b   Kanakapalli, Deepa ^a   Buck, Steven ^a   Gen, Sheng Wu ^b   Ravindranath, Yaddanapudi ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Chemotherapy; Cisplatin; Drug resistance; MKP 1; Osteosarcoma

Indexed keywords

CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRIPTOLIDE;

APOPTOSIS; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; NORTHERN BLOTTING; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BONE NEOPLASMS; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DUAL SPECIFICITY PHOSPHATASE 1; DUAL-SPECIFICITY PHOSPHATASES; FLOW CYTOMETRY; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; OSTEOSARCOMA; PHOSPHORYLATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 56749173830     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21727     Document Type: Article

References (25)

1. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-320.
2. Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007;251:1-16.
3. Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: Meeting summary. Clin Cancer Res 2003;9:5442-5453.
4. Pizzo PA, Poplack DG. Principle and practice of pediatric oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
5. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790.
6. Man TK, Chintagumpala M, Visvanathan J, et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 2005;65:8142-8150.
7. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial. J Clin Oncol 2002;20:426-433.
8. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
9. Sanchez-Perez I, Murguia JR, Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998;16:533-540.
10. Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 1995;20:117-122.
11. Wu GS. Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev 2007;26:579-585.
12. Losa JH, Parada Cobo C, Viniegra JG, et al. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 2003;22:3998-4006.
13. Seki K, Yoshikawa H, Shiiki K, et al. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother Pharmacol 2000;45:199-206.
14. Wang Z, Xu J, Zhou JY, et al. Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Res 2006;66:8870-8877.
15. Yan M, Dai T, Deak JC, et al. Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 1994;372:798-800.
16. Small GW, Shi YY, Higgins LS, et al. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 2007;67:4459-4466.
17. Isfort RJ, Cody DB, Lovell G, et al. Analysis of oncogenes, tumor suppressor genes, autocrine growth-factor production, and differentiation state of human osteosarcoma cell lines. Mol Carcinog 1995;14:170-178.
18. Inaba H, Glibetic M, Buck S, et al. Interferon-gamma sensitizes osteosarcoma cells to Fas-induced apoptosis by up-regulating Fas receptors and caspase-8. Pediatr Blood Cancer 2004;43:729-736.
19. Ozgen U, Savasan S, Buck S, et al. Comparison of DiOC(6)(3) uptake and annexin V labeling for quantification of apoptosis in leukemia cells and non-malignant T lymphocytes from children. Cytometry 2000;42:74-78.
20. Savasan S, Buck S, Ozdemir O, et al. Evaluation of cytotoxicity by flow cytometric drug sensitivity assay in childhood T-cell acute lymphoblastic leukemia. Leuk Lymphoma 2005;46:833-840.
21. Peng B, English MW, Boddy AV, et al. Cisplatin pharmacokinetics in children with cancer. Eur J Cancer 1997;33:1823-1828.
22. Veal GJ, Dias C, Price L, et al. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clin Cancer Res 2001;7:2205-2212.
23. Zhao Q, Shepherd EG, Manson ME, et al. The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: Attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. J Biol Chem 2005;280:8101-8108.
24. Chen TH, Kao YC, Chen BC, et al. Dipyridamole activation of mitogen-activated protein kinase phosphatase-1 mediates inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression in RAW 264.7 cells. Eur J Pharmacol 2006;541:138-146.
25. Sanchez-Perez I, Martinez-Gomariz M, Williams D, et al. CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene 2000;19:5142-5152.